The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business.

The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business. “ ...

The acquisition also advances Lantheus' capabilities with the addition of Evergreen's radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business. "Today marks a ...

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

Lantheus (LNTH) Holdings announced that it has completed its previously announced acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company. The acquisition was first ...

BEDFORD, Mass. - Lantheus Holdings, Inc. (NASDAQ: LNTH), a leader in the radiopharmaceutical industry, announced today the completion of its acquisition of Evergreen Theragnostics, Inc., a ...